|
|
| VGX
Co-Founder and Chief Medical Officer to Chair Vaccine Discovery
and Commercialization Conference
|
| Blue
Bell, PA – May 22, 2006 – |
|
VGX Pharmaceuticals announced today that Dr. David
B. Weiner, the Company’s Co-Founder, Chairman of the Scientific
Advisory Board and Dr. C. Jo White, Chief Medical Officer, will co-chair
the Vaccine Discovery and Commercialization Conference 
from May 23 to 24, 2006 at the Sheraton Philadelphia City Center in Philadelphia,
PA. Drs. Weiner and White were selected as chairpersons based on their
extensive expertise in discovering and developing novel vaccines for human
application.
Dr. Weiner is considered a founder of the area of DNA vaccines, and his
laboratory published the first DNA vaccine paper addressing HIV infection.
In collaboration with others, Dr. Weiner helped to initiate the first
FDA approved clinical trial of a DNA vaccine (HIV env/rev) as a therapy
as well as the first prophylactic DNA vaccine trial, and he was a member
of the committee that authored the FDA’s “points to consider
document” establishing the guidelines for clinical evaluation of
DNA vaccines. Dr. Weiner’s laboratory published the first work reporting
that immune responses from HIV DNA vaccine can induce cellular responses
in a primate, and can induce some level of protection in a primate. He
has over 90 publications in the area of DNA vaccines (270 publications
over all).
Dr. White has over 18 years of clinical and product development experience
in the biopharmaceutical industry with over 13 years dedicated to clinical
developments of several FDA-approved vaccines. She worked at Merck with
Dr. Margaret Liu to file the first IND for a DNA influenza vaccine in
the early 90s. She filed the initial BLA for the cold adapted influenza
vaccine while she was at Aviron. Dr. White has worked on several BLAs
and MAAs and has made multiple presentations to the FDA and the ACIP on
data from clinical studies of various viral vaccines, resulting not only
in licensure of 4 vaccines in the US and Europe and but also universal
immunization recommendations by the ACIP for varicella vaccine.
According to the Conference web site (http://www.marcusevans.com), Vaccine
Discovery and Commercialization Conference is an international conference
on examining the science, technology, and business aspects of infectious
diseases and how to effectively address this challenge to public health.
This conference will strive to provide participants with valuable insight
on emerging platforms being explored to design effective next generation
vaccines; innovative technologies for vaccine delivery; clinical trials
and vaccine production issues; regulatory compliance; and constructive
dialogue to ferment strategic outlines for vaccine discovery and commercialization.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2006 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
